NEW YORK (GenomeWeb) – Agena Bioscience announced today that it has signed an agreement to market its MassArray Dx system with HeartGenetics' HeartDecode genetic testing software and cardiovascular assays.
The HeartDecode software is designed to generate clinically actionable reports for HeartGenetics' suite of CE-IVD marked genetic testing kits, which include assays to assess individual risk for various cardiovascular conditions such as hereditary thrombophilia and arterial hypertension, as well as tests for clopidogrel, warfarin, and simvastatin pharmacogenetics.
Under the terms of their alliance, HeartGenetics will offer HeartDecode software and assays designed specifically for use with MassArray Dx mass spectrometry-based genetic analysis system, which is CE-IVD marked in Europe and available for research use only in the US.
Additional terms were not disclosed.